Pyxis Extends Cash Runway to H1 2028, Sets Mid-2027 Phase 3 Start
PYXS sits 60% above its 52-week low of $1.03.
Summary
Pyxis now says quarter-end cash plus net proceeds from its October public offering will fund operations into the first half of 2028, roughly a year beyond the Q2 2027 runway it guided in August. That October raise brought in $102.8 million net, which is what buys the extra time. The company also laid out a global Phase 3 trial start for mid-2027, with FDA dose-selection feedback expected in Q1 2027 as the gate before it. Safety looks clean so far, with no new signals across 35 evaluable patients. The runway removes near-term financing pressure, but the release gives no cash balance or prior-period comparison, so the size of the cushion is unclear. Q1 2027 FDA feedback is the next hard checkpoint for the Phase 3 plan. For the third quarter, Pyxis posted a loss of 24 cents a share and net income of USD -19.984 million.
At the time of this announcement, PYXS was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.5M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.